← Back to all trials
Completed
NCT05258071
A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)
Conditions: Parkinson Disease
Sex: All
Ages: 55 Years – 85 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 104
Sponsor: Integrative Research Laboratories AB
Location: Hôpital Neurologique Pierre Wertheimer Bron
Summary
This is a Phase 2b study investigating the efficacy and safety of pirepemat as adjunct therapy on falls frequency in patients with Parkinson disease. Pirepemat is taken for 84 days.
Eligibility Criteria
Inclusion Criteria:
1. Male or female 55-85 years of age, inclusive.
2. Diagnosis of idiopathic Parkinson's disease, according to the UK Parkinson's disease Society Brain Bank criteria.
3. Montreal Cognitive Assessment (MoCA) score of ≥10 and \
Source: ClinicalTrials.gov (NCT05258071). StuddyBuddy aggregates publicly available trial information.
